Grifols Therapeutics
As of the edition of 20 October 2026, Grifols Therapeutics runs 9 drugs, 8 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Stopped | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Human immunoglobulin g | Ended 2015 (orphan exclusivity) | 0 |
| Albumin human | none listed | 0 |
| .alpha.1-proteinase inhibitor human | Ended 1999 (computed from the first US licence) | 2 |
| Human coagulation factor viii | Ended 1986 (computed from the first US licence) | 0 |
| Hepatitis b immune globulin | Ended 1989 (computed from the first US licence) | 0 |
| Antithrombin iii human | Ended 2003 (computed from the first US licence) | 4 |
| Rabies immune globulin | Ended 1986 (computed from the first US licence) | 0 |
| Rho (d) immune globulin | Ended 1983 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Grifols Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 1 trials led
- Lungs and airways: 1 trials led